- WuXi Biologics has signed a license and research service agreement with Vertex Pharmaceuticals for a preclinical trispecific T-cell Engager targeting B-cell mediated autoimmune diseases.
- The agreement includes an upfront payment, milestone and royalty eligibility, and the provision of contract research and development services by WuXi Biologics.
WuXi Biologics has announced a license and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T-cell Engager (TCE) aimed at treating B-cell mediated autoimmune diseases. Under the agreement, Vertex will obtain exclusive global rights to develop and commercialise the preclinical TCE programme.
The collaboration covers a trispecific TCE designed to address autoimmune diseases driven by B-cell activity. WuXi Biologics will receive an upfront payment and may earn development, regulatory, and sales milestone payments, as well as royalties on future sales.
In addition to licensing the programme, WuXi Biologics will provide Vertex with contract research and development services for novel next-generation TCEs. The work will be supported by WuXi Biologics’ integrated discovery and development platforms, aligned with its CRDMO operating model.
“We are delighted to support Vertex’s efforts to bring forward transformative medicines for serious diseases through the study of this TCE. The collaboration reflects the company’s discovery service capabilities and its integrated CRDMO approach.”
Dr. Chris Chen, CEO of WuXi Biologics
Mark Bunnage, Chief Scientific Officer at Vertex, said the agreement provides “another important tool to accelerate our efforts to advance new medicines” as the company explores the potential of the trispecific TCE.
